Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-96345 SCHEMBL5419354 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5077901 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL29386897 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5673687 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL1447963 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419344 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL675160 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL675159 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419350 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9743556 | 0.95 | TACR1 (0.90) | TACR1CACNA1FCHRM5CACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-7214692-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | claimed |
| US-20050085414-A1 | Novel medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | claimed |
| EP-0812185-B1 | USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH | GILLETTE CO (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020052351-A1 | Novel medical use for tachykinin antagonists | GLAXO GROUP LIMITED | 2002-05-02 | — | — | US | claimed |
| EP-0812185-A2 | USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1997-12-17 | — | — | EP | claimed |
| WO-1996026712-A2 | USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1996-09-06 | — | — | WO | claimed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-0812185-B1 | USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH | GILLETTE CO (US) | 2002-07-03 | — | — | EP | disclosed |
| US-5854004-A | Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path | BOEHRINGER INGLEHEIM GMBH (DE) | 1998-12-29 | — | — | US | disclosed |
| EP-0621901-B1 | PROCESS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING A RECEPTOR-DEPENDENT CELLULAR SIGNAL TRANSDUCTION PATHWAY | BOEHRINGER INGELHEIM INT (DE) | 1998-04-15 | — | — | EP | disclosed |
| EP-0621901-A1 | PROCESS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING A RECEPTOR-DEPENDENT CELLULAR SIGNAL TRANSMISSION PATH | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1994-11-02 | — | — | EP | disclosed |
| WO-1993011257-A2 | PROCESS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING A RECEPTOR-DEPENDENT CELLULAR SIGNAL TRANSMISSION PATH | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | TACR1 91/4885CACNA1F 317/4885CHRM5 410/4885 |
| US-20050085414-A1 | Novel medical use for tachykinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CACNA1F 633/4885CHRM5 263/4885 |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | TACR1 288/4885CACNA1F 298/4885CHRM5 793/4885 |
| US-20020052351-A1 | Novel medical use for tachykinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CACNA1F 657/4885CHRM5 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.